Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation

Transplantation

Volumn 85, Issue 9, 2008, Pages 1290-1293

  Vianna, Rodrigo M ^a   Mangus, Richard S ^a   Fridell, Jonathan A ^a   Weigman, Sheila ^a   Kazimi, Marwan ^a   Tector, Joseph ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intestinal transplantation; Rabbit antithymocyte globulin; rATG; Rejection; Rituximab; Thymoglobulin; Transplant outcomes

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEROID THERAPY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VISCERA;

EID: 43449133599     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816dd450     Document Type: Conference Paper

References (24)

1. Abu-Elmagd KM. Intestinal transplantation for short bowel syndrome and gastrointestinal failure: Current consensus, rewarding outcomes, and practical guidelines. Gastroenterology 2006; 130(2 suppl 1): S132.
2. Kaufman SS. Small bowel transplantation: Selection criteria, operative techniques, advances in specific immunosuppression, prognosis. Curr Opin Pediatr 2001; 13: 425.
3. Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: Historical notes, principles and controversies. Pediatr Transplant 2002; 6: 193.
4. Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005; 5: 1430.
5. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003; 75: 1512.
6. Farmer DG, McDiarmid SV, Edelstein S, et al. Induction therapy with interleukin-2 receptor antagonist after intestinal transplantation is associated with reduced acute cellular rejection and improved renal function. Transplant Proc 2004; 36: 331.
7. Langnas A, Chinnakotla S, Sudan D, et al. Intestinal transplantation at the University of Nebraska Medical Center: 1990 to 2001. Transplant Proc 2002; 34: 958.
8. Nishida S, Levi DM, Moon JI, et al. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients. Transplant Proc 2006; 38: 1747.
9. Grant D. 2007 Interim Analysis of the Intestine Tranplant Registry. XI International Small Bowel Transplant Association Congress, 2007.
10. Ma H, Wang J, Wang J, et al. Features of chronic allograft rejection on rat small intestine transplantation. Pediatr Transplant 2007; 11: 165.
11. Kato T, Selvaggi G, Gaynor J, et al. Expanded use of multivisceral transplantation for small children with concurrent liver and intestinal failure. Transplant Proc 2006; 38: 1705.
12. Farmer DG, McDiarmid SV, Edelstein S, et al. Improved outcome after intestinal transplantation at a single institution over 12 years. Transplant Proc 2004; 36: 303.
13. Bonnefoy-Berard N, Flacher M, Revillard JP. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 1992; 79: 2164.
14. Beiras-Fernandez A, Chappell D, Hammer C, et al. Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a non-human primate model. Transpl Immunol 2006; 15: 273.
15. Bogetti D, Jarzembowski TM, Sankary HN, et al. Hepatic ischemia/ reperfusion injury can be modulated with thymoglobulin induction therapy. Transplant Proc 2005; 37: 404.
16. Bogetti D, Sankary HN, Jarzembowski TM, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005; 19: 507.
17. Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 2005; 242: 480.
18. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: A decade of experience at a single center. Ann Surg 2001; 234: 404.
19. Ruiz P, Garcia M, Pappas P, et al. Mucosal vascular alterations in isolated small-bowel allografts: Relationship to humoral sensitization. Am J Transplant 2003; 3: 43.
20. Jordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
21. Abu-Elmagd KM, Zak M, Stamos JM, et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation 2004; 77: 1719.
22. Quintini C, Kato T, Gaynor JJ, et al. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc 2006; 38: 1755.
23. Kato T, Tzakis AG, Selvaggi G, et al. Intestinal and multivisceral transplantation in children. Ann Surg 2006; 243: 756.
24. Ruiz P, Perez MT, Garcia M, et al. Semiquantitative measurement of mucosal fibrosis as a means of assessing chronic injury in bowel allografts. Transplant Proc 2002; 34: 874.